Cardamyst FDA Approval Status
Last updated by Judith Stewart, BPharm on Dec 31, 2023.
FDA Approved: No
Brand name: Cardamyst
Generic name: etripamil
Dosage form: Nasal Spray
Company: Milestone Pharmaceuticals Inc.
Treatment for: Paroxysmal Supraventricular Tachycardia
Cardamyst (etripamil) is a novel calcium channel blocker nasal spray in development for the treatment of paroxysmal supraventricular tachycardia and atrial fibrillation with a rapid ventricular rate (AFib-RVR).
- Paroxysmal supraventricular tachycardia (PSVT) is a type of arrhythmia characterized by episodes of rapid heartbeats often exceeding 150 to 200 beats per minute.
- Cardamyst contains etripamil, a short-acting calcium channel blocker with a rapid onset of action that works to quickly restore normal heart rhythm.
- Cardamyst is self-administered as a nasal spray and is absorbed into the bloodstream in less than 10 minutes through the blood vessels in the inner lining of the nose.
- Positive results from pivotal Phase 3 RAPID trial demonstrated that etripamil was twice as effective and three times as fast as a placebo in restoring normal heart rhythm for patients suffering from PSVT.
- Cardamyst is the conditionally approved brand name for etripamil nasal spray.
Development timeline for Cardamyst
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
